ApprovedIn stock
Semaglutide
GLP-1 receptor agonist · Lyophilized powder · 2–8°C
Approved in the EU for type 2 diabetes and chronic weight management. Glucagon-like peptide-1 (GLP-1) receptor agonist that slows gastric emptying and modulates appetite signaling via hypothalamic GLP-1 receptors.
PURITY
99.6%
FORM
Lyophilized
STORAGE
2–8°C
Dosage
1
Same-day dispatch on orders before 14:00 CET
Cold-chain shipping with phase-change gel packs
Batch KP-SMG-2604-A · COA available
Mechanism
How semaglutide works
Semaglutide is a long-acting GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. Two amino-acid substitutions (Aib in position 8, Arg in position 34) and a C18 fatty-acid side chain extend its half-life to ~165 hours, enabling once-weekly dosing.
In clinical use it slows gastric emptying, increases insulin secretion in a glucose-dependent manner, suppresses glucagon, and modulates appetite signaling in the hypothalamic arcuate nucleus.
Indications
EU regulatory status
- Approved by EMA for type 2 diabetes mellitus (Ozempic®, Rybelsus®)
- Approved for chronic weight management in adults with BMI ≥ 30, or ≥ 27 with comorbidity (Wegovy®)
- Prescription-only — supply requires a valid prescription from a registered EU physician